Strain-area loop in drug-induced (Selexipag (Uptravi(®))) afterload reduction of the right ventricular in pulmonary arterial hypertension

Strain-area loop in drug-induced (Selexipag (Uptravi(®))) afterload reduction of the right ventricular in pulmonary arterial hypertension - SALDIAPAH

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46728

Enrollment

Registered

2018-05-24

Start date

2018-09-19

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary arterial hypertension raised blood pressure in the pulmonary artery

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - men and female patiënts, aged betweent 18 and 75 years old - PAH WHO group 1 - NYHA II-III - decision to start with Selexipag/Uptravi(®) has already been taken - legally capable, informed consent

Exclusion criteria

Exclusion criteria: - pulmonary hypertension WHO group 2-5 - other prostacyclin usage

Design outcomes

Primary

Measure	Time frame
Primary endpoints are characteristics of the strain-area loop; slope systolic deformation (Sslope), slope diastolic deformation (Dslope).	—

Secondary

Measure	Time frame
Secondary endpoints - occurrence of cardiovascular events and hospital admissions in the first two years after starting selexipag - characteristics of strain-area loop; intersection with the X-axis (RVEDA), intersection with the Y-axis (peakstrain)	—

Countries

Netherlands

Outcome results